KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

OnabotulinumtoxinA Treatment for Masseter Muscle Prominence: 6-Month Safety and Efficacy Results, Including Patient-Reported Outcomes, From a Phase 3, Randomized, Placebo-Controlled, Multiregional Trial.

Jiaming Sun, Lei Wang, Yan Wu, Shannon Humphrey, Shyi-Gen Chen, William McGillivray, Shu-Hung Huang, Yuguang Zhang, Grace Pan, Catherine Foley, Elisabeth Lee, Joan-En Chang-Lin, Donna L Faletto, Vaishali Patel, Beta Bowen, Mitchell F Brin

Aesthet Surg J 46(5) 486-494

PMID41092464
PMCIDPMC13064654
DOI10.1093/asj/sjaf204
发表日期2025-10-15
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 7 张 PMC Figure,均未识别为 KM 图:Figure 1.:图注未提示 KM 曲线;Figure 2.:图注未提示 KM 曲线;Figure 3.:图注未提示 KM 曲线;Figure 4.:图注未提示 KM 曲线;Figure 5.:图注未提示 KM 曲线;另有 2 张未列出。
摘要

摘要

BACKGROUND: Masseter muscle prominence (MMP) may be aesthetically bothersome to some individuals, leading them to seek treatment for a slimmer lower face. OBJECTIVES: The aim of this study was to evaluate the safety and efficacy of onabotulinumtoxinA for the treatment of MMP, including patient-reported outcomes (PROs). METHODS: This was a prospective, multicenter trial including a randomized, double-blind, placebo-controlled period (Days 1-180) in which adults rated Grade 4 or 5 (marked/very marked) on the investigator-assessed MMP Scale (MMPS) were randomized to onabotulinumtoxinA 72 U or placebo. Efficacy endpoints were assessed at Day 90. The primary endpoint was ≥2-grade improvement from baseline on the investigator-assessed MMPS. Secondary endpoints included achieving Grade ≤3 on the MMPS and participant-assessed MMPS-Participant (MMPS-P), ≥2-grade improvement on the participant-assessed MMPS-P, and change from baseline in lower-facial width. Outcomes were assessed using validated measures. Adverse events (AEs) were monitored. RESULTS: Of 376 enrolled participants (onabotulinumtoxinA, n = 283; placebo, n = 93), 310 (82.4%) completed the study. At Day 90, a greater proportion of onabotulinumtoxinA-treated participants vs placebo achieved MMPS ≥2-grade improvement (51.2% vs 2.2%, P < .0001), and more onabotulinumtoxinA-treated participants vs placebo achieved the secondary endpoints (all P < .0001), with a mean lower-facial width reduction of -5.24 mm for onabotulinumtoxinA vs -0.04 mm for placebo (P < .0001). Participants reported benefits for onabotulinumtoxinA vs placebo in self-perceived change in MMP, treatment satisfaction, and psychosocial impact. Improvements were sustained through Day 180. Most AEs were mild, nonserious, and resolved. CONCLUSIONS: OnabotulinumtoxinA effectively reduced the appearance of MMP and improved PROs, with effects lasting up to 6 months and a favorable safety profile.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(7,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Proportion of participants achieving (A) ≥2-grade improvement from baseline on the investigator-assessed MMPS and (B) ≥2-grade improvement on the participant-assessed MMPS-P through Day 180. * P < .0001 vs placebo; ^ nominal P < .02 vs placebo; + nominal P < .0001 vs placebo. MMPS, Masseter Muscle Prominence Scale; MMPS-P, Masseter Muscle Prominence Scale—Participant; onabotA, onabotulinumtoxinA.
非 KM Figure
Figure 2.Proportion of participants achieving (A) Grade ≤3 on the investigator-assessed MMPS and (B) Grade ≤3 on the participant-assessed MMPS-P through Day 180. Error bars represent 95% CIs. * P < .0001 vs placebo; + nominal P < .0001 vs placebo. MMPS, Masseter Muscle Prominence Scale; MMPS-P, Masseter Muscle Prominence Scale—Participant; onabotA, onabotulinumtoxinA.
非 KM Figure
Figure 3.Representative photos of participants with ≥2-grade improvement on the investigator-assessed MMPS and participant-assessed MMPS-P before treatment and at Day 90 after treatment with onabotulinumtoxinA 72 U. All participants reported being “satisfied” or “very satisfied” at posttreatment time points. (A) A 43-year-old male patient from Taiwan before treatment (MMPS: left, 5; right, 5; MMPS-P: 5) and (B) at Day 90 (MMPS: left, 3; right, 3; MMPS-P: 2). (C) A 30-year-old female patient from China before treatment (MMPS: left, 4; right, 4; MMPS-P: 4) and (D) at Day 90 (MMPS: left, 3; right, 3; MMPS-P: 4). (E) A 40-year-old female patient from China before treatment (MMPS: left, 5; right, 5; MMPS-P: 5) and (F) at Day 90 (MMPS: left, 3; right, 3; MMPS-P: 3). (G) A 31-year-old female patient from Canada before treatment (MMPS: left, 4; right, 4; MMPS-P: 4) and (H) at Day 90 (MMPS: left, 2; right, 2; MMPS-P: 1). MMPS, Masseter Muscle Prominence Scale; MMPS-P, Masseter Muscle Prominence Scale—Participant.
非 KM Figure
Figure 4.Least-squares mean change from baseline in lower-facial width through Day 180. * P < .0001 vs placebo; + nominal P < .0001 vs placebo. OnabotA, onabotulinumtoxinA.
非 KM Figure
Figure 5.Participants reporting at least minimal improvement from baseline in lower facial shape on PSAC through Day 180. The PSAC assesses change in lower face shape on a 7-point scale ranging from “much worse” to “much improved.” * P < .0001 vs placebo. + nominal P < .0001 vs placebo. OnabotA, onabotulinumtoxinA; PSAC, Participant Self-Assessment of Change.
非 KM Figure
Figure 6.LFSQ endpoints through Day 180. (A) Participants reporting being “very satisfied” or “satisfied” with the effect of treatment on the LFSQ-TXSAT (follow-up version). The LFSQ-TXSAT follow-up version measures treatment satisfaction on a 5-point scale ranging from “very satisfied” to “very dissatisfied.” Nominal P < .0001 vs placebo at all time points. (B) Improvement in appearance-related psychosocial impact associated with MMP as assessed by the LFSQ-IA. Baseline mean (standard deviation) LFSQ-IA summary score: onabotA, 15.23 (5.91); placebo, 14.39 (5.50). The LFSQ-IA measures psychosocial impact associated with lower face appearance; range, 0-24; lower scores indicate less psychosocial impact and decreases from baseline signify improvement. Nominal P < .0001 vs placebo at all time points. LFSQ, Lower Facial Shape Questionnaire; LFSQ-IA, Lower Facial Shape Questionnaire—Impact Assessment; LFSQ-TXSAT, Lower Facial Shape Questionnaire—Treatment Satisfaction Assessment; LS, least squares; onabotA, onabotulinumtoxinA; SE, standard error of the mean.
非 KM Figure
Figure 7.Participants reporting being “not at all bothered” or “a little bothered” after treatment on the PGIB through Day 180. PGIB measures level of bother associated with MMP on a 5-point scale, ranging from “not at all bothered” to “extremely bothered.” At baseline, 93.5% and 91.3% of participants in the onabotulinumtoxinA and placebo groups, respectively, reported being “somewhat bothered,” “a lot bothered,” or “extremely bothered” by the appearance of their lower face. Nominal P < .0001 vs placebo at all time points. OnabotA, onabotulinumtoxinA; PGIB, Participant Global Impression of Bother; MMP, Masseter Muscle Prominence Scale.
非 KM Figure